News

Althea Technologies Appoints E.J. Brandreth to Vice President of Quality and Regulatory

7.15.2008 Althea Technologies Appoints E.J. Brandreth to Vice President of Quality and Regulatory

SAN DIEGO – July 15, 2008 -- Althea Technologies, Inc., a leading provider of innovative technologies and services for pharmaceutical development and manufacturing, announced today that E.J. Brandreth has joined the company as Vice President of Quality and Regulatory. In this role, Mr. Brandreth will be responsible for leading Althea’s quality and compliance programs, while overseeing the regulatory support activities, which are required to facilitate the launch of commercial manufacturing services.

“We are very excited to welcome E.J. Brandreth to Althea. The diverse experience he brings to the company is particularly valuable, as it spans everything from clinical development of innovative products, to the preparation and validation required for commercial launch of successful biopharmaceuticals. His background in clinical and commercial biological products is a perfect fit for the expanding scope of projects at Althea,” stated Dr. Magda Marquet, President and Co-CEO of Althea Technologies.

Mr. Brandreth brings over fifteen years of experience in the regulatory and quality assurance fields for the biotechnology and pharmaceutical industries. Prior to joining Althea Technologies, he was Vice President of Quality at Favrille, Inc., where he had oversight of Quality Control, Quality Assurance, Validation and Metrology. In the course of his career he has managed the validation of 11 different biotechnology facilities, and led the Process Validation Programs for five CBER/EMEA product launches. Previous to Favrille, Mr. Brandreth was Senior Director of QA at BioMarin Pharmaceuticals, Inc. where he supported a variety of clinical products and launched two commercial products. Prior to that, he held management positions in QA, Validation and Regulatory Affairs at IDEC Pharmaceuticals, where he assisted in the development and launch of Zevalin® and Rituxan®, CBER’s first approved monoclonal antibody for cancer. Additionally, Mr. Brandreth has helped to develop two Parenteral Drug Association (PDA) technical reports.

E.J. Brandreth added, “I am very pleased to join the outstanding team of professionals here at Althea Technologies. I’ve watched the company’s growth and I am really happy that I can call upon my experience to help assure the quality, compliance and facility validation efforts underway, which will best serve Althea’s clients. I’m joining Althea as the activities focused upon the release of the newly constructed state-of-the-art commercial-scale facility head into high gear, so I will be able to jump right in as we write this exciting new chapter in the company’s history.”

 

About Althea Technologies, Inc.

Althea Technologies, a leading San Diego-based pharmaceutical services firm, provides critical manufacturing services that support researchers worldwide in their advancement of novel therapies and efforts to apply new genomic information. Althea’s services include cGMP contract manufacturing of recombinant proteins, DNA-based therapeutics and vaccines, and aseptic filling.